Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study

Gantner P.; Reinhart S.; Partisani M.; Baldeyrou M.; Batard M-L; Bernard-Henry C.; Cheneau C.; de Mautort E.; Priester M.; Fafi-Kremer S.; Muret P.; Rey D.

首页> 外文期刊>HIV medicine >Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study

【24h】

Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study

机译：在病毒学抑制的HIV-1感染患者中改用恩曲他滨，替诺福韦和利比韦林单片治疗：一项队列研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectivesEmtricitabine/tenofovir/rilpivirine as a single-tablet regimen (STR) is widely used without licence in treatment-experienced patients. The purpose of this retrospective observational study was to assess viral suppression of ART-experienced patients switching to STR.

机译：目的恩曲他滨/替诺福韦/利比韦林单片治疗方案（STR）被广泛用于未经治疗的患者。这项回顾性观察研究的目的是评估接受过ART治疗的转为STR的患者的病毒抑制作用。

著录项

来源
《HIV medicine》 |2015年第2期|共5页
作者
Gantner P.; Reinhart S.; Partisani M.; Baldeyrou M.; Batard M-L; Bernard-Henry C.; Cheneau C.; de Mautort E.; Priester M.; Fafi-Kremer S.; Muret P.; Rey D.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词
antiretroviral; efficacy; pharmacokinetic; rilpivirine; safety; single tablet regimen; switch;

机译：抗逆转录病毒;疗效;药代动力学;利比韦林;安全性;单片方案;切换;

相似文献

外文文献
中文文献
专利

1. Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study [J] . Gantner P., Reinhart S., Partisani M., HIV medicine . 2015,第2期

机译：在病毒学抑制的HIV-1感染患者中改用恩曲他滨，替诺福韦和利比韦林单片治疗：一项队列研究
2. Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects [J] . C. Allavena, E. Dailly, V. Reliquet, The Journal of Antimicrobial Chemotherapy . 2014,第10期

机译：从替诺福韦/ Emtricitabine和Nevirapine切换到替诺福韦/培养宾宾/瑞培单片体单片体中的病毒学抑制，HIV-1感染受试者
3. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen [J] . Armenia D., Di Carlo D., Calcagno A., The Journal of Antimicrobial Chemotherapy . 2017,第3期

机译：预先存在的NRTI和NNRTI抗性对维持病毒学抑制的抗病患者，其转向替诺福韦/百日公鸡/瑞霉素单片机方案的HIV-1感染患者
4. Virological Outcome of Tenofovir plus Abacavir-based Regimens in Previously HIV Suppressed Patients (RECOVER STUDY) [C] . S. Moreno, M.J. Perez Elias, J.A. Terron International AIDS Conference . 2004

机译：以前艾滋病病毒抑制患者在替诺福韦加上基于Abacavir的病毒学结果（恢复研究）
5. Cost effectiveness analysis of abacavir/lamivudine versus tenofovir/emtricitabine combination therapy as part of highly active antiretroviral therapy in treatment naive HIV-infected patients. [D] . Giguere, Pierre. 2010

机译：阿巴卡韦/拉米夫定与替诺福韦/恩曲他滨联合疗法作为高活性抗逆转录病毒疗法治疗未受HIV感染的患者的成本效益分析。
6. Week 48 Results of EMERALD: A Phase 3 Randomized Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD) Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed HIV-1-infected Adults [O] . Chloe Orkin, Jean-Michel Molina, Joel Gallant, 2017

机译：EMERALD的第48周结果：第3阶段的非劣效性研究评估了从加强蛋白酶抑制剂（bPI）加恩曲他滨（FTC）/替诺福韦富马酸替诺福韦酯（TDF）转换为每日一次（QD）的功效和安全性）在病毒学上被抑制感染了HIV-1的成年人中Darunavir / Cobicistat / Emtricitabine / Tenofovir Alafenamide（D / C / F / TAF）的单片治疗方案（STR）
7. Week 48 Results of EMERALD: A Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD), Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-infected Adults [O] . Chloe Orkin, Jean-Michel Molina, Joel Gallant, 2017

机译：每周48个祖母绿的结果：第3期，随机的非劣升性研究，评估从增强蛋白酶抑制剂（BPI）加上的促蛋白（BPI）和替尼罗韦（FTC）/ Tenofovir Disoproxil umarate（TDF）方案的疗效和安全性对一次每日（QD ），在病毒学抑制的单片机/ Cobicistat / Emtricisabine / enftricitabine / Tenofovir Alafenainide（D / C / F / TAF）的单片植物（str），HIV-1感染的成年人

Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study

摘要

著录项

相似文献

相关主题

期刊订阅